MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 2 | 1.0 |
Embryo Transfer/*standards | 2 | 1.0 |
Female | 144 | 0.0 |
Humans | 512 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 5 | 0.0 |
Pregnancy Outcome | 3 | 1.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Review Literature | 2 | 1.0 |
Animals | 313 | 0.0 |
Apoptosis/physiology | 5 | 1.0 |
Blotting, Western | 33 | 0.0 |
Enzyme Inhibitors/pharmacology | 12 | 0.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Mice | 234 | 0.0 |
Mice, Transgenic | 160 | 5.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Oxidative Stress/*physiology | 11 | 11.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 405 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 186 | 0.0 |
Superoxide Dismutase/metabolism | 18 | 21.0 |
Ubiquitin/*metabolism | 5 | 2.0 |
Amyotrophic Lateral Sclerosis/metabolism | 6 | 54.0 |
Cells, Cultured | 28 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Mutation/genetics/physiology | 3 | 9.0 |
Nerve Degeneration/pathology | 3 | 20.0 |
Superoxide Dismutase/*genetics/*metabolism | 23 | 95.0 |
Transfection | 35 | 0.0 |
Cell Line | 31 | 0.0 |
Child, Preschool | 8 | 0.0 |
Glutathione Peroxidase/genetics/metabolism | 2 | 28.0 |
Infant | 6 | 0.0 |
Male | 149 | 0.0 |
Middle Aged | 96 | 0.0 |
RNA, Messenger/metabolism | 17 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 19 | 0.0 |
Superoxide Dismutase/genetics/metabolism | 24 | 70.0 |
Adult | 81 | 0.0 |
Amyotrophic Lateral Sclerosis/*metabolism | 6 | 33.0 |
Astrocytes/*enzymology | 2 | 25.0 |
Glycosylation End Products, Advanced/*metabolism | 2 | 4.0 |
Immunohistochemistry | 62 | 0.0 |
Lipid Peroxidation/genetics | 3 | 37.0 |
Mutation/genetics | 15 | 1.0 |
Spinal Cord/*metabolism | 5 | 15.0 |
Superoxide Dismutase/*genetics | 145 | 74.0 |
Cell Death/genetics | 3 | 7.0 |
*Gene Therapy | 2 | 0.0 |
Gene Transfer Techniques | 4 | 0.0 |
Genetic Vectors | 6 | 0.0 |
Neuroglia/metabolism/pathology | 2 | 14.0 |
Adenoviridae/genetics | 4 | 0.0 |
Cattle | 6 | 0.0 |
Cell Survival/drug effects/physiology | 2 | 2.0 |
Dopamine/metabolism | 2 | 1.0 |
Neurons/cytology/*drug effects/*metabolism | 2 | 22.0 |
Oxidative Stress/genetics/physiology | 2 | 100.0 |
Rats | 33 | 0.0 |
Superoxide Dismutase/genetics/*metabolism | 33 | 68.0 |
Comparative Study | 58 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Tumor Cells, Cultured | 27 | 0.0 |
Animals, Newborn | 10 | 1.0 |
Disease Progression | 33 | 1.0 |
Kinetics | 20 | 0.0 |
Models, Neurological | 6 | 4.0 |
*Mutation | 53 | 1.0 |
Superoxide Dismutase/*genetics/metabolism | 37 | 80.0 |
Amyotrophic Lateral Sclerosis/*metabolism/pathology | 3 | 25.0 |
Cell Survival/drug effects/genetics | 5 | 22.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Electron Transport Complex I | 2 | 5.0 |
Electron Transport Complex II | 2 | 7.0 |
Electron Transport Complex III/metabolism | 2 | 14.0 |
Electron Transport Complex IV/metabolism | 6 | 13.0 |
Energy Metabolism | 2 | 1.0 |
Enzyme Activation/drug effects/genetics | 3 | 14.0 |
Motor Neurons/drug effects/*metabolism/pathology | 2 | 50.0 |
Multienzyme Complexes/metabolism | 4 | 2.0 |
Mutagenesis, Site-Directed | 17 | 0.0 |
Oxidoreductases/metabolism | 2 | 2.0 |
Succinate Dehydrogenase/metabolism | 2 | 5.0 |
Amino Acid Substitution | 26 | 1.0 |
Amyotrophic Lateral Sclerosis/enzymology | 2 | 33.0 |
Cell Death/drug effects | 5 | 3.0 |
Cell Differentiation | 3 | 0.0 |
Cell Survival/drug effects | 8 | 0.0 |
*Copper | 3 | 50.0 |
Gene Expression | 16 | 0.0 |
Manganese/*metabolism | 2 | 28.0 |
Mitochondria/enzymology | 2 | 1.0 |
Neurons/*enzymology/pathology | 2 | 13.0 |
Oxidative Stress | 22 | 6.0 |
Mitochondrial Swelling | 2 | 50.0 |
Mutation | 75 | 0.0 |
Oxidative Phosphorylation | 3 | 8.0 |
Oxygen/metabolism | 6 | 2.0 |
Spinal Cord/enzymology | 3 | 33.0 |
Neuroprotective Agents/*metabolism | 2 | 6.0 |
Neurotoxins/*pharmacology | 2 | 20.0 |
Age Factors | 13 | 0.0 |
Alanine/genetics | 8 | 7.0 |
Amyotrophic Lateral Sclerosis/*drug therapy/genetics | 4 | 100.0 |
Disease Models, Animal | 81 | 3.0 |
Glycine/genetics | 9 | 9.0 |
Motor Activity/drug effects | 7 | 13.0 |
Superoxide Dismutase/genetics | 40 | 51.0 |
Survival Analysis | 11 | 0.0 |
Case-Control Studies | 7 | 0.0 |
Polymorphism, Genetic/genetics | 4 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Risk Factors | 3 | 0.0 |
Aged | 62 | 0.0 |
Amyotrophic Lateral Sclerosis/*genetics/*pathology | 3 | 75.0 |
Family Health | 19 | 1.0 |
Japan | 7 | 0.0 |
Pedigree | 42 | 0.0 |
*Point Mutation | 26 | 2.0 |
Aged, 80 and over | 19 | 0.0 |
Amyotrophic Lateral Sclerosis/*genetics | 46 | 74.0 |
Chromosome Mapping/*methods | 3 | 1.0 |
Cohort Studies | 2 | 0.0 |
DNA Mutational Analysis/methods | 2 | 0.0 |
Exons/genetics | 11 | 0.0 |
Molecular Chaperones/*genetics | 2 | 9.0 |
Cell Count | 10 | 1.0 |
Inclusion Bodies/metabolism/pathology | 2 | 25.0 |
Parkinson Disease/metabolism/pathology | 2 | 33.0 |
Reference Values | 6 | 0.0 |
Spinal Cord/metabolism/pathology | 7 | 33.0 |
Administration, Oral | 2 | 0.0 |
Blotting, Western/methods | 7 | 3.0 |
Dose-Response Relationship, Drug | 16 | 0.0 |
Drug Interactions | 3 | 0.0 |
Glial Fibrillary Acidic Protein/metabolism | 3 | 1.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Nitric Oxide/metabolism | 5 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 4 | 1.0 |
Statistics, Nonparametric | 2 | 0.0 |
Injections, Spinal | 3 | 8.0 |
Superoxide Dismutase/biosynthesis/*genetics | 8 | 66.0 |
Amyotrophic Lateral Sclerosis/enzymology/genetics | 6 | 100.0 |
Mutation/*genetics | 17 | 1.0 |
Amyotrophic Lateral Sclerosis/*metabolism/mortality | 2 | 100.0 |
Antioxidants/metabolism | 6 | 6.0 |
Cell Death/drug effects/physiology | 4 | 9.0 |
Glutathione Peroxidase/genetics | 2 | 25.0 |
Mitochondria/*metabolism | 4 | 2.0 |
Motor Neurons/cytology/*metabolism | 3 | 60.0 |
Reactive Oxygen Species/metabolism | 11 | 3.0 |
Survival Rate | 13 | 0.0 |
Adolescent | 13 | 0.0 |
Copper/*blood | 2 | 15.0 |
Erythrocytes/enzymology | 11 | 2.0 |
Superoxide Dismutase/*blood | 3 | 11.0 |
Motor Neurons/pathology | 15 | 48.0 |
Amyotrophic Lateral Sclerosis/enzymology/*genetics/physiopathology | 2 | 100.0 |
Axotomy | 3 | 11.0 |
Copper/chemistry/*metabolism | 3 | 100.0 |
Mice, Knockout | 9 | 0.0 |
Molecular Chaperones/*metabolism | 2 | 3.0 |
Cell Aging | 2 | 2.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Cytosol/metabolism | 3 | 0.0 |
DNA/metabolism | 4 | 0.0 |
Down-Regulation | 2 | 0.0 |
Hydrogen Peroxide/pharmacology | 5 | 2.0 |
Microscopy, Confocal | 3 | 0.0 |
*Oxidative Stress | 10 | 4.0 |
Oxygen/*metabolism | 5 | 3.0 |
Phenotype | 31 | 0.0 |
Phosphorylation | 8 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Time Factors | 27 | 0.0 |
Behavior, Animal/drug effects | 2 | 4.0 |
Cell Count/methods | 2 | 3.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Mice, Inbred Strains | 7 | 0.0 |
Molecular Chaperones/genetics/metabolism | 2 | 15.0 |
Rats, Wistar | 2 | 0.0 |
Microscopy, Immunoelectron | 8 | 1.0 |
Motor Neuron Disease/*enzymology/genetics | 5 | 100.0 |
Protein Subunits | 2 | 0.0 |
Amino Acid Sequence | 35 | 0.0 |
Models, Molecular | 12 | 0.0 |
Molecular Sequence Data | 57 | 0.0 |
Phylogeny | 2 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Apoptosis | 12 | 0.0 |
*DNA Helicases | 2 | 0.0 |
Mice, Inbred C57BL | 27 | 0.0 |
Neurons/*cytology/*metabolism | 2 | 18.0 |
*Saccharomyces cerevisiae Proteins | 6 | 0.0 |
Antioxidants/*metabolism | 8 | 8.0 |
Brain/pathology | 3 | 0.0 |
Brain Chemistry/*physiology | 2 | 3.0 |
Glutathione/metabolism | 7 | 3.0 |
Neurons/metabolism | 4 | 1.0 |
Oxidative Stress/physiology | 14 | 20.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 21 | 0.0 |
Amyotrophic Lateral Sclerosis/*genetics/metabolism | 4 | 80.0 |
Linkage (Genetics) | 9 | 0.0 |
Neurofilament Proteins/genetics | 3 | 23.0 |
Amyotrophic Lateral Sclerosis/*enzymology/*genetics | 15 | 100.0 |
Free Radicals/metabolism | 10 | 19.0 |
Gene Expression Regulation, Enzymologic/*physiology | 4 | 4.0 |
Mice, Neurologic Mutants | 5 | 4.0 |
Mutation/*physiology | 8 | 7.0 |
Oxidative Stress/genetics | 2 | 8.0 |
Brain/*physiology | 2 | 1.0 |
Copper/*metabolism | 10 | 11.0 |
Enzyme Stability | 2 | 1.0 |
Motor Neuron Disease/enzymology/*genetics | 5 | 83.0 |
Protein Denaturation | 2 | 0.0 |
Superoxide Dismutase/chemistry/*genetics | 5 | 83.0 |
Thermodynamics | 3 | 0.0 |
Zinc/*metabolism | 2 | 3.0 |
Binding Sites | 16 | 0.0 |
Cloning, Molecular | 15 | 0.0 |
Copper/metabolism | 14 | 21.0 |
DNA Primers | 22 | 0.0 |
Protein Structure, Secondary | 7 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
Superoxide Dismutase/chemistry/*genetics/metabolism | 4 | 100.0 |
Variation (Genetics) | 3 | 0.0 |
Animals, Genetically Modified | 8 | 3.0 |
Brain/metabolism/pathology | 4 | 3.0 |
Rats, Sprague-Dawley | 10 | 0.0 |
Superoxide Dismutase/blood/*genetics | 3 | 75.0 |
Catalase/metabolism | 6 | 9.0 |
Cell Survival | 8 | 0.0 |
Glutathione Peroxidase/metabolism | 4 | 11.0 |
Lipid Peroxidation/drug effects | 2 | 3.0 |
Multivariate Analysis | 2 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Regression Analysis | 2 | 0.0 |
Apoptosis/*genetics | 5 | 2.0 |
*Gene Expression | 2 | 0.0 |
Gene Expression Profiling | 5 | 0.0 |
In Situ Hybridization | 8 | 0.0 |
Mice, Transgenic/genetics | 9 | 16.0 |
Carrier Proteins/genetics/metabolism | 3 | 1.0 |
Central Nervous System/*metabolism/pathology/physiopathology | 2 | 50.0 |
Dimerization | 10 | 0.0 |
Glutamic Acid/*metabolism | 5 | 20.0 |
Molecular Weight | 3 | 0.0 |
Alzheimer Disease/*genetics | 2 | 0.0 |
Chromosome Mapping | 25 | 0.0 |
Chromosomes, Human, Pair 21/*genetics | 3 | 3.0 |
Genome, Human | 3 | 0.0 |
Polymerase Chain Reaction | 22 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Nerve Degeneration/*genetics/physiopathology | 2 | 100.0 |
Aging/*metabolism | 3 | 1.0 |
Fetus | 2 | 0.0 |
Infant, Newborn | 8 | 0.0 |
Neurons/cytology/*enzymology | 3 | 15.0 |
Superoxide Dismutase/*metabolism | 17 | 43.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Caspases/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Cytochrome c Group/metabolism | 2 | 1.0 |
Mitochondria/*enzymology | 4 | 3.0 |
Mitochondrial Proteins/metabolism | 2 | 10.0 |
Signal Transduction/physiology | 2 | 0.0 |
Superoxide Dismutase/*biosynthesis/genetics | 10 | 55.0 |
Superoxides/metabolism | 14 | 5.0 |
Cell Survival/physiology | 4 | 2.0 |
Cysteine Endopeptidases/*metabolism | 4 | 1.0 |
Enzyme Activation | 6 | 0.0 |
Multienzyme Complexes/*metabolism | 3 | 2.0 |
Neuroblastoma | 8 | 4.0 |
Nitric Oxide/*metabolism | 3 | 2.0 |
Nitric-Oxide Synthase/metabolism | 4 | 3.0 |
Proteasome Endopeptidase Complex | 7 | 1.0 |
Teratocarcinoma | 2 | 7.0 |
Up-Regulation | 5 | 0.0 |
Amyotrophic Lateral Sclerosis/genetics/metabolism/*pathology | 4 | 100.0 |
Cysteine Endopeptidases/metabolism | 5 | 2.0 |
Molecular Chaperones/*genetics/metabolism | 2 | 40.0 |
Nerve Tissue Proteins/genetics/*metabolism | 2 | 1.0 |
Ubiquitins/metabolism | 5 | 3.0 |
Amyotrophic Lateral Sclerosis/genetics/*metabolism | 11 | 78.0 |
Cell Death/physiology | 7 | 9.0 |
Protein Binding | 17 | 0.0 |
Protein Structure, Tertiary | 10 | 0.0 |
Ubiquitin/metabolism | 4 | 1.0 |
Neurons/metabolism/*pathology | 3 | 10.0 |
Clinical Trials | 2 | 0.0 |
Neuroprotective Agents/*therapeutic use | 2 | 8.0 |
Point Mutation/genetics | 2 | 0.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Motor Neurons/*drug effects | 2 | 25.0 |
Spinal Cord/*pathology | 4 | 20.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Glutamic Acid/metabolism | 2 | 4.0 |
Mitochondria/metabolism | 5 | 1.0 |
Models, Animal | 2 | 0.0 |
*Nerve Degeneration | 2 | 8.0 |
Neurofilament Proteins/metabolism | 10 | 17.0 |
Motor Skills/drug effects | 2 | 40.0 |
Neuroprotective Agents/*pharmacology | 2 | 2.0 |
Amyotrophic Lateral Sclerosis/*pathology | 5 | 35.0 |
Spinal Cord/pathology | 12 | 16.0 |
Amyotrophic Lateral Sclerosis/*genetics/pathology | 6 | 85.0 |
Caspases/metabolism | 6 | 0.0 |
Enzyme Activation/genetics | 5 | 5.0 |
*Transgenes | 2 | 4.0 |
Age of Onset | 16 | 1.0 |
Amyotrophic Lateral Sclerosis/epidemiology/*genetics | 3 | 75.0 |
*Chromosome Mapping | 10 | 0.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Haplotypes/genetics | 2 | 0.0 |
Lod Score | 11 | 1.0 |
Aerobiosis | 2 | 8.0 |
Antioxidants/pharmacology | 7 | 3.0 |
Ascorbic Acid/pharmacology | 2 | 3.0 |
Calcineurin/*metabolism | 3 | 18.0 |
Calcium/metabolism | 5 | 0.0 |
Enzyme Activation/drug effects/physiology | 2 | 3.0 |
Oxidation-Reduction | 19 | 1.0 |
Point Mutation | 14 | 0.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Brain/*metabolism | 3 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Mice, Mutant Strains | 6 | 0.0 |
*Phenotype | 3 | 1.0 |
Amyotrophic Lateral Sclerosis/*enzymology/genetics/pathology | 5 | 100.0 |
*Apoptosis | 3 | 0.0 |
Lumbosacral Region | 3 | 10.0 |
Motor Neurons/*enzymology/pathology | 4 | 80.0 |
Spinal Cord/pathology/ultrastructure | 4 | 66.0 |
Vacuoles/*pathology/ultrastructure | 2 | 100.0 |
DNA Mutational Analysis | 11 | 0.0 |
Family | 5 | 1.0 |
Genes, Dominant | 11 | 1.0 |
Genetic Screening | 3 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Mitochondria/*enzymology/pathology/ultrastructure | 2 | 100.0 |
Motor Neurons/metabolism/pathology | 2 | 22.0 |
Superoxide Dismutase/analysis/*genetics/*metabolism | 2 | 100.0 |
Heterozygote | 5 | 0.0 |
Brain/metabolism | 3 | 0.0 |
Organ Specificity | 4 | 0.0 |
Oxygen Consumption | 2 | 0.0 |
Spinal Cord/metabolism | 10 | 19.0 |
Chromosomes, Human, Pair 2 | 2 | 1.0 |
Genotype | 17 | 0.0 |
Hyalin/*metabolism | 4 | 66.0 |
Molecular Chaperones/*genetics/*metabolism | 2 | 66.0 |
Rabbits | 3 | 0.0 |
Amyloid beta-Protein Precursor/genetics | 2 | 4.0 |
Fetal Blood/*cytology | 2 | 1.0 |
Transplantation, Heterologous | 3 | 0.0 |
Microscopy, Electron | 12 | 0.0 |
Base Sequence | 51 | 0.0 |
Escherichia coli/genetics | 5 | 0.0 |
Genetic Complementation Test | 4 | 0.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Electromyography | 6 | 3.0 |
Gene Expression Regulation, Enzymologic/physiology | 5 | 5.0 |
*Heterozygote Detection | 2 | 1.0 |
Motor Neuron Disease/*genetics/physiopathology | 3 | 60.0 |
Motor Neurons/*physiology | 7 | 12.0 |
Genetic Vectors/administration & dosage/genetics | 2 | 8.0 |
Injections, Intramuscular | 2 | 1.0 |
Muscle, Skeletal/pathology | 2 | 3.0 |
Amyotrophic Lateral Sclerosis/*drug therapy | 2 | 33.0 |
Models, Biological | 6 | 0.0 |
Catalase/genetics/*metabolism | 2 | 66.0 |
Treatment Failure | 2 | 0.0 |
Oxidoreductases/*metabolism | 2 | 4.0 |
Ultraviolet Rays | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Motor Activity | 4 | 8.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Alleles | 6 | 0.0 |
Gene Frequency/genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Axonal Transport/*genetics | 2 | 66.0 |
Escherichia coli | 3 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Cell Death | 9 | 2.0 |
Interferon Type II/metabolism | 2 | 0.0 |
Ions | 2 | 2.0 |
Signal Transduction | 4 | 0.0 |
Exons | 12 | 0.0 |
Italy | 7 | 1.0 |
Frameshift Mutation | 2 | 0.0 |
Motor Neurons/enzymology/pathology | 5 | 100.0 |
*Amyotrophic Lateral Sclerosis/genetics/metabolism/pathology | 2 | 100.0 |
Astrocytes/enzymology/pathology | 2 | 50.0 |
Neurons/enzymology/pathology | 3 | 37.0 |
*Genetic Markers | 2 | 0.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Hydrogen Peroxide/*pharmacology | 3 | 5.0 |
Motor Neuron Disease/enzymology/genetics | 2 | 100.0 |
Oxidative Stress/drug effects/*physiology | 2 | 9.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism | 2 | 3.0 |
Recombinant Proteins/metabolism | 10 | 0.0 |
Amyotrophic Lateral Sclerosis/*genetics/*physiopathology | 2 | 66.0 |
Motor Neurons/physiology | 5 | 10.0 |
Neurons/physiology | 3 | 2.0 |
Apoptosis/drug effects/genetics | 2 | 5.0 |
Biological Transport | 5 | 0.0 |
Brain Stem/metabolism | 2 | 15.0 |
Cell Culture Techniques | 2 | 0.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Motor Neurons/*metabolism | 5 | 23.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 2 | 0.0 |
Apoptosis/genetics | 3 | 1.0 |
Gene Expression Regulation, Enzymologic | 14 | 1.0 |
Reactive Oxygen Species/*metabolism | 5 | 3.0 |
Superoxide Dismutase/*genetics/physiology | 2 | 100.0 |
Amino Acid Sequence/genetics | 3 | 1.0 |
Base Sequence/genetics | 3 | 0.0 |
Homozygote | 2 | 0.0 |
Mutation, Missense/*genetics | 4 | 2.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Spinal Cord/cytology/metabolism | 3 | 20.0 |
Transgenes | 5 | 1.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Nerve Tissue Proteins/chemistry/*genetics | 2 | 4.0 |
*Sequence Deletion | 3 | 0.0 |
Embryo | 3 | 0.0 |
NG-Nitroarginine Methyl Ester/pharmacology | 3 | 6.0 |
English Abstract | 7 | 0.0 |
Amyotrophic Lateral Sclerosis/*enzymology/*genetics/pathology | 2 | 66.0 |
Motor Neurons/enzymology/*pathology | 3 | 100.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
Mitochondria/drug effects/metabolism | 2 | 6.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Proteins/metabolism | 5 | 0.0 |
Motor Neurons/*metabolism/pathology | 4 | 66.0 |
Spinal Cord/*metabolism/pathology | 3 | 25.0 |
Amyotrophic Lateral Sclerosis/genetics/*metabolism/*pathology | 3 | 75.0 |
*Gene Deletion | 3 | 0.0 |
Amyotrophic Lateral Sclerosis/*genetics/*metabolism/pathology | 3 | 60.0 |
Gene Dosage | 6 | 1.0 |
Hydroxyl Radical/metabolism | 3 | 15.0 |
Cerebellum/pathology | 2 | 6.0 |
Mice, Inbred BALB C | 5 | 0.0 |
*Radiation Tolerance | 2 | 3.0 |
Amyotrophic Lateral Sclerosis/enzymology/genetics/*pathology | 2 | 100.0 |
Calcium/*metabolism | 2 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
*Protein Folding | 3 | 2.0 |
Spinal Cord/enzymology/pathology | 6 | 85.0 |
Hydrogen Peroxide/metabolism | 6 | 4.0 |
Vitamin K/pharmacology | 4 | 21.0 |
Xanthine Oxidase/pharmacology | 2 | 22.0 |
Brain Chemistry | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 14 | 0.0 |
Alzheimer Disease/enzymology | 2 | 13.0 |
Brain/enzymology | 3 | 1.0 |
Chromosomes, Human, Pair 21/genetics | 5 | 12.0 |
Cell Survival/genetics | 2 | 3.0 |
Tyrosine/*analogs & derivatives/metabolism | 2 | 3.0 |
DNA Fragmentation | 3 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
In Situ Nick-End Labeling | 5 | 0.0 |
Superoxide Dismutase/genetics/*physiology | 4 | 57.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Neurons/*physiology | 4 | 2.0 |
Restriction Mapping | 6 | 0.0 |
Cytosol/enzymology | 3 | 1.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 2 | 2.0 |
Proteins/*metabolism | 4 | 0.0 |
Superoxide Dismutase/immunology/*metabolism | 2 | 100.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Hamsters | 6 | 0.0 |
Nerve Tissue Proteins/*metabolism | 3 | 1.0 |
Aging/metabolism | 4 | 2.0 |
Brain Stem/enzymology/pathology | 2 | 50.0 |
Astrocytes/*metabolism | 2 | 3.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Zinc/metabolism | 6 | 7.0 |
Gene Therapy/*methods | 3 | 0.0 |
Amyotrophic Lateral Sclerosis/metabolism/*pathology | 2 | 50.0 |
Motor Neurons/*pathology | 5 | 26.0 |
Histocytochemistry | 2 | 0.0 |
Karyotyping | 15 | 0.0 |
Motor Activity/genetics | 2 | 25.0 |
Trisomy | 3 | 2.0 |
Hela Cells | 8 | 0.0 |
Isoenzymes/genetics | 6 | 1.0 |
Transcription, Genetic | 8 | 0.0 |
Cerebral Cortex/cytology | 2 | 8.0 |
Green Fluorescent Proteins | 5 | 0.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Amyotrophic Lateral Sclerosis/genetics/metabolism | 2 | 66.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Cerebral Cortex/*metabolism | 2 | 3.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Mutation/physiology | 4 | 3.0 |
Axonal Transport/*physiology | 3 | 37.0 |
Kinesin/metabolism | 2 | 18.0 |
Mutation, Missense | 4 | 0.0 |
Excitatory Amino Acid Agonists/pharmacology | 3 | 18.0 |
Hippocampus/*metabolism | 2 | 2.0 |
Superoxide Dismutase/biosynthesis/genetics | 4 | 66.0 |
Astrocytes/drug effects/*metabolism | 2 | 9.0 |
Amyotrophic Lateral Sclerosis/*genetics/*metabolism | 4 | 100.0 |
Ditiocarb/pharmacology | 2 | 11.0 |
Alzheimer Disease/metabolism | 2 | 3.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Parkinson Disease/metabolism | 3 | 17.0 |
Solubility | 5 | 0.0 |
Dithiothreitol/pharmacology | 2 | 2.0 |
DNA Damage | 3 | 0.0 |
*Reactive Oxygen Species | 3 | 11.0 |
DNA Primers/chemistry | 5 | 0.0 |
Electric Stimulation | 4 | 1.0 |
Genes, Recessive | 5 | 1.0 |
Neural Conduction/physiology | 2 | 5.0 |
Motor Neuron Disease/enzymology | 2 | 100.0 |
Motor Neurons/*enzymology | 2 | 33.0 |
Species Specificity | 6 | 0.0 |
Choline O-Acetyltransferase/metabolism | 3 | 2.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Postmortem Changes | 2 | 2.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Motor Neurons/enzymology/*physiology | 2 | 100.0 |
Clone Cells | 3 | 0.0 |
HL-60 Cells | 2 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
*Disease Models, Animal | 4 | 1.0 |
*Mice, Transgenic | 2 | 4.0 |
Transduction, Genetic | 2 | 0.0 |
3,4-Dihydroxyphenylacetic Acid/metabolism | 2 | 7.0 |
Amino Acid Transport System X-AG | 3 | 25.0 |
Aspartic Acid/metabolism | 2 | 7.0 |
Microdialysis | 2 | 7.0 |
DNA/genetics | 3 | 0.0 |
Gene Frequency | 3 | 0.0 |
Amyotrophic Lateral Sclerosis/enzymology/*genetics | 19 | 95.0 |
Crystallography, X-Ray | 4 | 0.0 |
Protein Conformation | 7 | 0.0 |
Amyotrophic Lateral Sclerosis/complications/*genetics/pathology | 2 | 100.0 |
Brain/metabolism/*pathology | 2 | 6.0 |
Cell Line, Tumor | 8 | 0.0 |
Macromolecular Substances | 9 | 0.0 |
Protein Binding/genetics | 3 | 1.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Molecular Chaperones/metabolism | 2 | 4.0 |
Motor Neuron Disease/*enzymology/genetics/pathology | 3 | 100.0 |
Protein Folding | 5 | 1.0 |
Amyotrophic Lateral Sclerosis/enzymology/*genetics/pathology | 8 | 100.0 |
Gene Expression/physiology | 2 | 0.0 |
Glial Fibrillary Acidic Protein/analysis | 4 | 2.0 |
Motor Neurons/chemistry/enzymology/pathology | 2 | 100.0 |
N-Methylaspartate/pharmacology | 2 | 14.0 |
Nitric Oxide Donors/pharmacology | 2 | 3.0 |
Superoxide Dismutase/*chemistry/metabolism | 4 | 100.0 |
Neurons/metabolism/ultrastructure | 2 | 11.0 |
Aging | 4 | 1.0 |
Chromosomes, Human, Pair 21 | 13 | 12.0 |
Motor Neuron Disease/genetics | 2 | 40.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Amyotrophic Lateral Sclerosis/*genetics/physiopathology | 4 | 57.0 |
Exons/*genetics | 3 | 0.0 |
Chelating Agents/*pharmacology | 4 | 30.0 |
Ditiocarb/*pharmacology | 2 | 25.0 |
Antioxidants/*pharmacology | 3 | 2.0 |
Molecular Chaperones/chemistry/*physiology | 2 | 100.0 |
Axonal Transport/genetics | 2 | 33.0 |
Amyotrophic Lateral Sclerosis/*enzymology/*genetics/physiopathology | 2 | 100.0 |
Neurology/trends | 2 | 66.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 3 | 2.0 |
Free Radicals/*metabolism | 3 | 21.0 |
Lipid Peroxidation | 3 | 2.0 |
*Amyotrophic Lateral Sclerosis | 2 | 50.0 |
Superoxide Dismutase/*analysis | 2 | 50.0 |
Genetic Markers | 10 | 0.0 |
Amyotrophic Lateral Sclerosis/enzymology/*genetics/*pathology | 3 | 100.0 |
Fatal Outcome | 3 | 0.0 |
Neurofilament Proteins/*analysis | 2 | 25.0 |
Nerve Degeneration/genetics | 2 | 28.0 |
Superoxide Dismutase/*deficiency/genetics | 3 | 75.0 |
Apoptosis/*physiology | 5 | 0.0 |
Superoxide Dismutase/genetics/metabolism/*physiology | 2 | 100.0 |
Bone Diseases/complications | 2 | 25.0 |
Bone and Bones/pathology | 2 | 9.0 |
Fractures, Spontaneous/*etiology | 2 | 25.0 |
Osteoporosis/*complications | 2 | 22.0 |
Dynein ATPase/metabolism | 2 | 22.0 |
Superoxide Dismutase/deficiency/genetics | 3 | 75.0 |
Action Potentials/physiology | 2 | 4.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
Caspase 1/metabolism | 2 | 10.0 |
Neuroblastoma/pathology | 2 | 6.0 |
Neurons/*pathology | 4 | 6.0 |
Reactive Oxygen Species | 7 | 6.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Brain/*enzymology | 2 | 1.0 |
Amyotrophic Lateral Sclerosis/enzymology/genetics/*metabolism | 3 | 100.0 |
Motor Neurons/metabolism | 4 | 25.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
*Proteasome Endopeptidase Complex | 2 | 3.0 |
Protein Subunits/metabolism | 2 | 4.0 |
Incidence | 2 | 0.0 |
Amyotrophic Lateral Sclerosis/*enzymology/genetics/*pathology | 2 | 100.0 |
Hyalin | 2 | 66.0 |
COS Cells | 5 | 0.0 |
Histidine/genetics | 3 | 5.0 |
DNA | 3 | 0.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Alanine | 2 | 2.0 |
Glycine | 4 | 5.0 |
Spinal Cord/*enzymology/pathology | 3 | 42.0 |
*Transcription, Genetic | 2 | 0.0 |
Oxidants/pharmacology | 2 | 3.0 |
ATP-Binding Cassette Transporters/*metabolism | 2 | 2.0 |
Catalase/*genetics | 2 | 18.0 |
Cell Division | 4 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Sequence Deletion | 4 | 0.0 |
Glycosylation End Products, Advanced/immunology/*metabolism | 2 | 66.0 |
Inclusion Bodies/*metabolism | 2 | 25.0 |
Antibodies | 4 | 0.0 |
Amyotrophic Lateral Sclerosis/genetics/pathology/physiopathology | 2 | 100.0 |
*Carrier Proteins | 2 | 0.0 |
Iodoacetamide/pharmacology | 2 | 12.0 |
Amyotrophic Lateral Sclerosis/*enzymology | 6 | 46.0 |
Transformation, Genetic | 2 | 1.0 |
Nitrates/metabolism | 2 | 10.0 |
Nitric Oxide/*physiology | 2 | 2.0 |
Electron Spin Resonance Spectroscopy | 3 | 1.0 |
Models, Chemical | 5 | 1.0 |
Peroxidase/*metabolism | 2 | 3.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
*Gene Expression Regulation, Enzymologic/drug effects | 2 | 4.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Transcription Factor, Sp1/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Isoenzymes/biosynthesis/genetics/metabolism | 3 | 10.0 |
Temperature | 3 | 0.0 |
Valine/genetics | 2 | 2.0 |
Caspase 1/*metabolism | 2 | 20.0 |
Mutagenesis | 2 | 0.0 |
Amyotrophic Lateral Sclerosis/*enzymology/genetics | 11 | 91.0 |
Catalysis | 2 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Microsatellite Repeats | 4 | 0.0 |
Mice, Transgenic/*genetics | 3 | 9.0 |
Precipitin Tests | 3 | 0.0 |
Amyotrophic Lateral Sclerosis/genetics | 4 | 57.0 |
Genes, Structural/genetics | 2 | 0.0 |
Isoenzymes/genetics/metabolism | 2 | 1.0 |
*Chromosome Aberrations | 3 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Axons/physiology | 3 | 6.0 |
Hydrogen Peroxide/*metabolism | 2 | 5.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Axons/*ultrastructure | 2 | 33.0 |
DNA/blood | 2 | 1.0 |
Genetic Screening/methods | 2 | 1.0 |
Down Syndrome/*genetics | 8 | 11.0 |
Axons/pathology | 4 | 12.0 |
Gene Expression Regulation, Enzymologic/*genetics | 2 | 3.0 |
Neurofilament Proteins/*genetics | 2 | 13.0 |
Dogs | 2 | 0.0 |
Amyotrophic Lateral Sclerosis/genetics/*metabolism/pathology | 2 | 66.0 |
Malondialdehyde/metabolism | 3 | 11.0 |
Paralysis/pathology | 2 | 66.0 |
Spinal Cord/chemistry | 2 | 33.0 |
Biological Markers | 3 | 0.0 |
Amyotrophic Lateral Sclerosis/*genetics/metabolism/*pathology | 2 | 66.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
*Gene Dosage | 2 | 2.0 |
Superoxide Dismutase/*chemistry | 4 | 80.0 |
Child | 11 | 0.0 |
Glutathione Peroxidase/blood | 2 | 5.0 |
Superoxide Dismutase/blood | 4 | 9.0 |
*Linkage (Genetics) | 3 | 0.0 |
Hand Strength/physiology | 2 | 18.0 |
In Vitro | 6 | 0.0 |
Amyotrophic Lateral Sclerosis/genetics/*pathology | 5 | 100.0 |
Motor Neurons/*physiology/ultrastructure | 2 | 66.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Cerebral Cortex/*enzymology | 2 | 18.0 |
Nerve Growth Factors/*pharmacology | 2 | 1.0 |
PC12 Cells | 4 | 1.0 |
Autopsy | 3 | 1.0 |
*DNA Damage | 2 | 0.0 |
Copper/*chemistry | 2 | 18.0 |
Free Radicals | 6 | 3.0 |
Histidine/chemistry | 2 | 4.0 |
Models, Statistical | 2 | 1.0 |
Spectrophotometry | 2 | 1.0 |
Tryptophan/chemistry | 2 | 5.0 |
Ischemic Attack, Transient/*metabolism/pathology | 2 | 50.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Spinal Cord/*enzymology | 3 | 33.0 |
Neurons/pathology | 4 | 3.0 |
Chromatography, Gel | 2 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Plasmids/metabolism | 6 | 0.0 |
Zinc/chemistry | 2 | 6.0 |
*Cation Transport Proteins | 3 | 1.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
DNA, Complementary | 4 | 0.0 |
Facial Nerve/pathology | 2 | 40.0 |
*Chromosome Deletion | 3 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Blotting, Southern | 11 | 0.0 |
Chromosome Banding | 7 | 0.0 |
Gene Library | 2 | 0.0 |
*Molecular Chaperones | 2 | 1.0 |
Amyotrophic Lateral Sclerosis/pathology/*physiopathology | 2 | 100.0 |
Nerve Degeneration/physiology | 2 | 11.0 |
Amyotrophic Lateral Sclerosis/*epidemiology/*genetics | 2 | 100.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Treatment Outcome | 3 | 0.0 |
*ATP-Binding Cassette Transporters | 2 | 1.0 |
Enzyme Stability/genetics | 2 | 7.0 |
Nerve Degeneration | 5 | 7.0 |
Prognosis | 2 | 0.0 |
Antigens, CD/metabolism | 2 | 0.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Superoxide Dismutase/chemistry/genetics/*metabolism | 2 | 100.0 |
Zinc/*chemistry | 2 | 18.0 |
Neurons/*metabolism | 2 | 0.0 |
Tissue Distribution | 6 | 0.0 |
Polymorphism, Genetic | 10 | 0.0 |
Point Mutation/*genetics | 2 | 0.0 |
*Exons | 3 | 0.0 |
Gene Amplification | 2 | 0.0 |
Gene Deletion | 3 | 0.0 |
Brain/enzymology/pathology | 2 | 18.0 |
Organ Size | 2 | 1.0 |
Fibroblasts/*enzymology | 2 | 5.0 |
Lipid Peroxidation/physiology | 2 | 18.0 |
Consensus Sequence | 2 | 0.0 |
Kidney | 2 | 0.0 |
Superoxide Dismutase/*chemistry/genetics/*metabolism | 4 | 80.0 |
Superoxide Dismutase/analysis/*metabolism | 2 | 100.0 |
Amyotrophic Lateral Sclerosis/genetics/pathology/*physiopathology | 2 | 100.0 |
Immunoblotting | 5 | 0.0 |
Heat | 2 | 0.0 |
Oxidative Stress/*genetics | 2 | 7.0 |
Saccharomyces cerevisiae/*genetics | 2 | 1.0 |
Amyotrophic Lateral Sclerosis/*enzymology/genetics/metabolism | 2 | 100.0 |
Chelating Agents/pharmacology | 2 | 2.0 |
Paraquat/pharmacology | 2 | 50.0 |
Heat-Shock Proteins/*biosynthesis | 2 | 10.0 |
Macaca mulatta | 2 | 0.0 |
Copper | 4 | 20.0 |
Glutathione Peroxidase/*metabolism | 2 | 14.0 |
Zinc | 4 | 16.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Motor Neuron Disease/*genetics | 3 | 37.0 |
Muscle, Skeletal/*enzymology | 2 | 4.0 |
Superoxide Dismutase/deficiency/*genetics | 3 | 100.0 |
Chromosome Aberrations/*genetics | 2 | 1.0 |
Chromosome Disorders | 2 | 0.0 |
*Chromosomes, Human, Pair 21 | 18 | 11.0 |
Cattle/*genetics | 3 | 2.0 |
Reproducibility of Results | 3 | 0.0 |
Sex Factors | 3 | 0.0 |
Mice, Inbred C3H | 3 | 0.0 |
Hybrid Cells | 5 | 0.0 |
Repetitive Sequences, Nucleic Acid/genetics | 2 | 2.0 |
Lymphocytes/*enzymology | 2 | 2.0 |
Scotland/epidemiology | 2 | 5.0 |
Cell Line, Transformed | 3 | 0.0 |
Superoxide Dismutase/biosynthesis/*genetics/metabolism | 2 | 100.0 |
Cercopithecus aethiops | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Amyotrophic Lateral Sclerosis/*enzymology/pathology | 2 | 66.0 |
Amyotrophic Lateral Sclerosis/etiology/*genetics | 2 | 66.0 |
DNA Probes | 4 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Drug Resistance | 2 | 0.0 |
Glutathione Reductase/metabolism | 2 | 13.0 |
Erythrocytes/*enzymology | 3 | 0.0 |
*Chromosome Disorders | 2 | 2.0 |
Annexin A5/metabolism | 2 | 2.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Lymphocytes | 2 | 1.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
Substrate Specificity | 2 | 0.0 |
Genes, Structural | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Acetylcysteine/pharmacology | 2 | 2.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Erythrocytes/metabolism | 2 | 1.0 |
Chromatography, Liquid | 2 | 1.0 |
Circular Dichroism | 2 | 0.0 |
Light | 2 | 0.0 |
Scattering, Radiation | 2 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Blood Group Antigens/*genetics | 2 | 1.0 |
Cricetulus | 4 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Alcohol Oxidoreductases/*genetics | 2 | 9.0 |
Chromosomes, Human, Pair 18 | 2 | 1.0 |
Chromosomes, Human, Pair 6 | 2 | 1.0 |
*Evolution | 2 | 1.0 |
Marsupialia/*genetics | 2 | 14.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Amino Acids/genetics | 2 | 6.0 |
Amyotrophic Lateral Sclerosis/metabolism/pathology | 2 | 66.0 |
Disulfides | 2 | 2.0 |
Hydrogen Peroxide/toxicity | 2 | 8.0 |
*Heat-Shock Proteins | 2 | 3.0 |
*Mutation, Missense | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Neuroblastoma/metabolism | 4 | 7.0 |
Down Syndrome/*enzymology | 2 | 28.0 |
Liver/metabolism | 2 | 0.0 |
Transfection/methods | 2 | 1.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Papio/*genetics | 2 | 11.0 |
Carbonic Anhydrases/blood | 2 | 66.0 |
Zinc/*blood | 3 | 12.0 |
Fibroblasts/*metabolism | 2 | 1.0 |
Microscopy, Fluorescence | 3 | 0.0 |
RNA Interference | 2 | 0.0 |
Anterior Horn Cells/*metabolism | 2 | 100.0 |
Haplotypes | 2 | 0.0 |
Isoenzymes/blood | 2 | 3.0 |
Chromosomes, Human, Pair 16/*genetics | 2 | 2.0 |
Chromosomes/*ultrastructure | 2 | 9.0 |
Hybrid Cells/ultrastructure | 2 | 7.0 |
Metals/metabolism | 2 | 14.0 |
Cebidae/*genetics | 3 | 23.0 |
Cebus/*genetics | 3 | 100.0 |
Neurons/drug effects/physiology | 2 | 9.0 |
Motor Neuron Disease/enzymology/*genetics/pathology | 2 | 100.0 |
Antioxidants/*therapeutic use | 2 | 6.0 |
Superoxide Dismutase/drug effects/*genetics/metabolism | 2 | 100.0 |
Vitamin K 3/pharmacology | 2 | 50.0 |
Astrocytes/metabolism | 2 | 2.0 |
Biotinylation | 2 | 1.0 |
Nerve Degeneration/*pathology | 2 | 22.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Superoxide Dismutase/genetics/*metabolism/pharmacology | 2 | 100.0 |
Microtubule-Associated Proteins/drug effects/metabolism | 2 | 25.0 |
Neurons/*metabolism/pathology | 2 | 3.0 |
